Besides tumors of the reproductive organs, related only to one of the two sexes, a growing body of data indicates significant differences in the onset and progression of oncological diseases common to men and women, as well as in responses and associated adverse events to therapies.
Numerical data indicate that men display higher incidence and lower survival than women have. Furthermore, the female immune system is more efficient than the male one.
Analyzing molecular data and understanding the mechanisms underlying the onset of each cancer, including gender specificities, represent a fundamental step toward a real personalized medicine.
